US 11389480
Human monoclonal antibody targeting TNFR2 for cancer immunotherapy
granted A61KA61K2039/505A61K35/17
Quick answer
US patent 11389480 (Human monoclonal antibody targeting TNFR2 for cancer immunotherapy) held by The United States of America, as represented by the Secretary, Department of Health and Human Services expires Mon Jul 14 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- The United States of America, as represented by the Secretary, Department of Health and Human Services
- Grant date
- Tue Jul 19 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Jul 14 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 41
- CPC classes
- A61K, A61K2039/505, A61K35/17, A61K47/6415, A61K47/6929